Korro Bio, Inc. Income Statement
KRRO|6 years of annual SEC 10-K data (FY2019-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Korro Bio, Inc. reported $2M in revenue and $84M in net loss for FY2025. Revenue has declined at a 32.6% compound annual rate over the past 6 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.49 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | $2.3M | $0 | $14.1M | $37.0M | $28.9M | $24.2M |
| SG&A Expense | $30.5M | $27.3M | $37.2M | $27.1M | $14.8M | $4.3M |
| R&D Expense | $63.6M | $57.3M | $60.9M | $37.4M | $18.8M | $12.0M |
| Operating Income | -$91.9M | -$84.5M | -$84.0M | -$27.6M | -$20.7M | -$16.3M |
| Interest Expense | - | - | $764.0K | $0 | - | -$174.0K |
| Income Tax | $141.0K | $27.0K | $15.0K | $35.0K | $0 | $0 |
| Net Income | -$83.6M | -$81.2M | -$84.7M | -$26.5M | -$18.7M | -$20.2M |
| EPS (Basic) | -$9.37 | -$53.08 | - | - | - | - |
| EPS (Diluted) | -$9.37 | -$53.08 | - | -$0.82 | -$2.29 | -$28.79 |
| Shares Outstanding | 9.4M | 8.0M | 34.6M | 34.0M | 30.8M | 2.1M |
| Operating Margin | -4047.1% | - | -597.3% | -74.5% | -71.4% | -67.3% |
| Profit Margin | -3680.4% | - | -602.0% | -71.7% | -64.8% | -83.5% |